Extract

This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A is the dose escalation phase for evaluating the safety and tolerability profile of PRN1371, a FGFR 1-4 Kinase inhibitor. Part B is the Cohort Expansion phase to further evaluate safety and tolerability, preliminary activity, PK, and PD in patients with FGFR genetic alterations.

Inclusion criteria

• Solid Tumors

Links

• ictrp
• nct